Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | Phase III study shows carfilzomib is an effective addition to standard myeloma therapy

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Keith Stewart (Mayo Clinic, Scottsdale, AZ) discusses the randomised, open-label, multicentre phase III ASPIRE study. The results of this study suggest carfilzomib combined with standard multiple myeloma therapy (combination of lenalidomide and dexamethasone) improves treatment responses in patients with relapsed or treatment-resistant multiple myeloma.